In a global insulin market of about 14 billion USD, China is number two in the number of patients, and with Takeda’s 6 billion and Eli Lilly’s 3 billion USD fine for concealing cancer risks of their diabetes drug Actos, Chinese companies such as Tonghua Dongbao are moving ahead to capture larger shares of the Chinese and international markets.
China Bio news release, April 17, 2014